Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Completed · Phase 2 · Has a placebo group

Conditions studied: PBC, Primary Biliary Cirrhosis

In brief

The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a 13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect of daily dosing with UDCA in combination with LUM001 or placebo.

Key facts

Study ID
NCT01904058
Run by
Mirum Pharmaceuticals, Inc.
People needed
66
Starts
2013-08-01
Expected to finish
2015-04-01
Last updated by the study team
2019-03-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.